# A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

> **NCT06921850** · PHASE3 · RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 40 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT06921850
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2026-12-21
- **Final completion:** 2029-03-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06921850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06921850, "A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06921850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*